

12/11/2018

...

Karl Herz
Managing Director
Bioclect Pty Ltd

Committee Secretary
Senate Foreign Affairs, Defence and Trade References Committee
PO Box 6100
Parliament House
Canberra, ACT 2600
Australia

**RE: Submission for Senate Inquiry on the Use of the Quinoline anti-malarial drugs
Mefloquine and Tafenoquine in the Australian Defence Force**

Thank you for the opportunity to provide evidence to the committee on 8 November 2018. I would like to provide some additional information to further clarify one area of my evidence on page 17 of the transcript and the sentence is highlighted below:

***Mr Herz:** Bioclect would like to thank the committee for the opportunity to appear before you today. As an individual I feel and as an organisation we feel for the plight of the veterans and what they are experiencing and hope that they receive all the help that they need. During the hearings, I have observed the overwhelming amount of information presented to the committee from various sources. Whilst the veterans' stories are harrowing, we believe that we need to respect the findings of the various regulators and their experts. We have been working with 60 Degrees Pharmaceuticals since 2013 on the commercialisation of tafenoquine, and we made a decision to license tafenoquine for malaria prevention for Australia and other countries in the region, the first new product in 20 years for malaria prevention in Australia.*

We have been helping 60 Degrees Pharmaceuticals with commercialisation of Tafenoquine since 2013. This help was provided by the consulting company Biointellect Pty Ltd which I am a director, employee and one of the owners. Whereas Bioclect Pty Ltd licenced Tafenoquine from 60 Degrees Pharmaceuticals under a Supply and Distribution Agreement executed 22nd September 2016 for Australia, NZ, PNG and various Pacific Islands.

I thought I should clarify timelines as to when Bioclect obtained the rights for Tafenoquine for these territories.

If you require further clarification, on any point, please let me know.

With best regards,

Karl Herz, B. App. Sc. (Biomedicine)
Managing Director
Bioclect Pty Ltd